Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tazemetostat · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| tazemetostat | DRUG | Dose Escalation Phase (Phase IIa): Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days; Dose Expansion Phase (Phase IIb): Tazemetostat (800 mg BID orally) in a therapeutic cycle of 28 days |
| HMPL-689 | DRUG | Dose Escalation Phase (Phase IIa): HMPL-689:20 mg and 30 mg, QD orally in a therapeutic cycle of 28 days. Dose Expansion Phase (Phase IIb): HMPL-689 (RP2D) in a therapeutic cycle of 28 days |
Tazemetostat is being studied for relapsed or refractory follicular lymphoma with EZH2 alterations and for relapsed or refractory lymphoma. It is an investigational small molecule developed by HUTCHMED (China) Limited for these oncology indications and is not yet approved for them.
Tazemetostat targets EZH2, an enzyme in the histone methyltransferase family. It acts as an EZH2 inhibitor, meaning it blocks the activity of this target. This mechanism is the basis for its investigation in lymphomas where EZH2 is implicated.
Tazemetostat is developed by HUTCHMED (China) Limited, which trades under the ticker HCM. The company is running clinical development of the drug in lymphoma indications, including relapsed or refractory follicular lymphoma with EZH2 alterations and relapsed or refractory lymphoma.
Tazemetostat is in Phase 2 clinical development. It has received FDA designations of Priority Review and Accelerated Approval. It remains an investigational agent and is not approved for the indications described here.
Tazemetostat has been studied in two completed Phase 2 trials. NCT05713110 evaluated tazemetostat in combination with HMPL-689 in patients with relapsed or refractory lymphoma, enrolling 61 patients. NCT05467943 evaluated tazemetostat in relapsed or refractory follicular lymphoma with EZH2 alterations, enrolling 42 patients.
Tazemetostat is an investigational drug in Phase 2 development for the lymphoma indications described here. It has received FDA Priority Review and Accelerated Approval designations, but the available information does not indicate approval for these specific relapsed or refractory lymphoma uses.